J. Darbá, Lisette Kaskens, Manuel Abecassis, J. Carrasco, Ricardo Vitorino, Matthew J. Taylor
{"title":"葡萄牙标准剂量伊马替尼耐药慢性髓系白血病患者达沙替尼与高剂量伊马替尼和尼洛替尼的成本效益","authors":"J. Darbá, Lisette Kaskens, Manuel Abecassis, J. Carrasco, Ricardo Vitorino, Matthew J. Taylor","doi":"10.1007/S40277-013-0027-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":101511,"journal":{"name":"PharmacoEconomics Spanish Research Articles","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide crónica resistente a la dosis estándar de imatinib en Portugal\",\"authors\":\"J. Darbá, Lisette Kaskens, Manuel Abecassis, J. Carrasco, Ricardo Vitorino, Matthew J. Taylor\",\"doi\":\"10.1007/S40277-013-0027-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":101511,\"journal\":{\"name\":\"PharmacoEconomics Spanish Research Articles\",\"volume\":\"47 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Spanish Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/S40277-013-0027-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Spanish Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/S40277-013-0027-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide crónica resistente a la dosis estándar de imatinib en Portugal